IDEXX Laboratories stock holds near 52-week low after strong Q2 growth
Published on 09/14/2026 at 13:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
IDEXX Laboratories stock (ISIN US45168D1046) closed at USD 504.88 on the Nasdaq on September 11, 2026, slipping 0.34% from the prior session while touching a new 52-week low around USD 502 despite robust earnings momentum.
Stock trades heavy near new 52-week low
According to an overview cited in a recent market report, IDEXX Laboratories stock ended the September 11, 2026 session at USD 504.88 on the Nasdaq after trading between an intraday high of USD 513.18 and a low of USD 501.00, based on S&P 500 component data that also showed unusually high turnover around 7.6 million shares and a market value near USD 39.8 billion.
A technical summary from a recent signal review flagged IDEXX Laboratories stock as marking a new 52-week low at roughly USD 502 on September 11, 2026, reinforcing the impression of sustained selling pressure as investors rotated out of some high-valuation healthcare names even as fundamentals remained solid.
Q2 2026 earnings beat and guidance raise
As a comparative analysis on Pluang reports, IDEXX Laboratories delivered a Q2 2026 earnings beat with earnings per share of USD 1.40 versus market expectations of USD 1.35, a positive surprise of USD 0.05 per share that was driven by strong revenue growth and operating leverage in its diagnostics-focused portfolio.
In the same overview, revenue for fiscal year 2025 is cited at USD 4.3 billion, with a net income margin of 25.03 percent, highlighting a structurally profitable business model that sets a historical benchmark for current performance even though these 2025 figures serve primarily as context rather than the latest reporting period for 2026.
According to the comparative note from Pluang, IDEXX Laboratories has raised its 2026 EPS guidance following recent quarterly results, signaling management confidence in demand for companion animal diagnostics and water testing despite near-term share price weakness.
Valuation premium and investor perspective
The same Pluang comparison notes that IDEXX Laboratories trades at a price-to-earnings ratio of about 35.47 based on recent data, underscoring a valuation premium relative to many broader healthcare peers and leaving the stock sensitive to shifts in interest rates and risk appetite.
With IDEXX Laboratories stock now close to its new 52-week low while still backed by a Q2 2026 earnings beat and higher full-year EPS guidance, the tension between short-term technical pressure and longer-term growth expectations is central to the current investment narrative.
Stock price level and market context
As of the close on September 11, 2026, IDEXX Laboratories stock traded at USD 504.88 on the Nasdaq, roughly in line with the indicated new 52-week low near USD 502, with a market capitalization around USD 39.8 billion, making the shares a sizable component within the US healthcare sector even as they trade below prior highs.
IDEXX Laboratories stock facts
- Company: IDEXX Laboratories, Inc.
- ISIN: US45168D1046
- Ticker: IDXX
- Trading venue: Nasdaq
- Price (as of September 11, 2026): 504.88 USD
- Market capitalization: 39.8 billion USD (as of September 11, 2026)
- Sector / Industry: Healthcare / Veterinary diagnostics
- Index membership: S&P 500
